Tissue Regenix Group (TRX)

 

TRX Share PerformanceMore

52 week high22.500 18/03/16
52 week low15.000 07/03/16
52 week change 4.950 (32.46%)
4 week volume4,640,099 28/12/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Tissue Regenix appoints Paul Devlin as group FD

Tissue Regenix Group announces the appointment of Paul Devlin as Group Finance Director and Company Secretary with...

Directorate Change

Notification of any change to a company’s board e.g. appointments/resignations/changes to important functions or executive responsibilities of a director

Hardman Research: a/c change: Not simply 11/12ths

TR1- NOTIFICATION OF MAJOR INTEREST IN SHARES

Notification of major interests in shares

TRX says DermaPure wins GPO agreement

Tissue Regenix Group announces that Tissue Regenix Wound Care Inc has secured a Group Purchasing Organisation (GPO...

DermaPure secures GPO agreement with Premier, Inc.

Statement regarding a contract entered into/awarded/signed

Tissue Regenix issues OrthoPureT XT update

Tissue Regenix Group said the early clinical data provided to support the CE mark application for OrthoPure XT (porcine ...

OrthoPureT XT update

Application by a company to a regulatory body for a product or service (e.g. approval to market a pharmaceutical product)

Fundamental DataMore

EPS-1.27
Dividend yield0 %

Equity Research (TRX)

edison investment research
Tissue Regenix Group Plc
19/10/2016
Tissue Regenix’s interim results are in line with our expectations and demonstrate the progress the company is making to achieve various milestones in each of its divisions. In particular, its Wound...
edison investment research
Tissue Regenix Group Plc
28/07/2016
Tissue Regenix’s (TRX) investment story is built on dCELL, a versatile regenerative medical technology, and its potential across the subsectors: wound care, orthopaedics and cardiac implants....
edison investment research
Tissue Regenix Group Plc
22/03/2016
Tissue Regenix’s (TRX’s) investment case is built on dCELL, a patented decellularised tissue scaffold. Wound care is a main driver for TRX’s growth and recent announcements demonstrate progress on...

Latest discussion posts More

  • Re: Proactive

    Sounds positive enough. Thought the least interesting was the appointment that sounded a bit like he's good at the doing the job we have appointed him for.. CL
    6-Jan-2017
    Chicken Lips
  • Proactive

    http://www.proactiveinvestors.co.uk/companies/amp/media_files/6687
    6-Jan-2017
    theprior
  • 20 paid

    Nice to see a few chunky buys going through today. Somebody's got a belief that TRX is going places. TP
    15-Dec-2016
    theprior

Users' HoldingsMore

Users who hold Tissue Regenix Group also hold..
LLOYDS GRP.30%
TESCO22%
SIRIUS MINERALS22%
BP22%
AVIVA17%

Codes & Symbols

ISINGB00B5SGVL29
SymbolsTRX, LSE:TRX, TRX.L, TRX:LN, LON:TRX, XLON:TRX